Ann: Cynata Technology Featured on Front Cover of Nature Medicine, page-2

Cynata’s Ground-Breaking MSC Technology Featured on Cover of Nature Medicine

Melbourne, Australia; 18 November 2020: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that its proprietary Cymerus™ MSC technology has been featured on the front cover of the latest issue of the prestigious journal, Nature Medicine.

The cover is also displayed on the journal’s website. The illustration (by Patton'd Studios, Melbourne) represents an induced pluripotent stem cell (iPSC)-derived mesenchymoangioblast colony, which is a crucial intermediate step in the Cymerus process.

This issue of Nature Medicine also includes the paper describing the Phase 1 clinical trial of CYP-001 in patients with steroid-resistant graft versus host disease (GvHD), which was recently published online in the first instance (as announced on 15 September 2020).

Dr Kilian Kelly, Cynata’s Chief Operating Officer, said: “We are honoured by the decision of the Nature Medicine editorial team to feature our ground-breaking research on the cover of the latest issue. This is further recognition of the importance of this study to the wider field of regenerative medicine. The publication of our paper online has already generated a great deal of interest in our technology, and we expect that to increase further as this issue is distributed to its many subscribers worldwide.”

The details of the paper describing the Phase 1 clinical trial of CYP-001 are as follows: Bloor AJC, Patel A, Griffin JE, Gilleece MH, Radia R, Yeung DT, Drier D, Larson LS, Uenishi GI, Hei D, Kelly K, Slukvin I and Rasko JEJ. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a Phase I, multi-centre, open label, dose-escalation study. Nat Med 26, 1720–1725 (2020).


But, but it's all just an unproven myth -